← Back to Home

Vision Improvements Last Two Years: Opus Reports Follow-up Results from Small Retinal Gene Therapy Trial

Visual improvements persisted through 24 months in three adults who received LCA5 gene therapy, while three adolescents showed early improvements. The findings support a Phase 3 trial, but more complete clinical data are still needed to determine whether efficacy can be reproduced and to assess safety.

By SURL BioNews

For people who have had severe visual impairment since early childhood, how long treatment-related changes last is as important as the extent of improvement. On October 15, Opus Genetics released follow-up data on a gene therapy for a rare inherited retinal disease: improvements in vision and light sensitivity in three adults who received OPGx-LCA5 persisted through 24 months. This is an early signal of sustained benefit that will undergo more rigorous testing in the upcoming Phase 3 trial.

The data, presented at the Retina in Rio 2026 meeting in Brazil, came from six low-dose participants, including three adults and three adolescents, who received 1 × 10¹⁰ vector genomes per eye. The therapy uses adeno-associated virus serotype 8 (AAV8) to deliver a functional LCA5 gene into photoreceptor cells, with the aim of restoring production of the lebercilin protein. Defects in this protein cause Leber congenital amaurosis type 5, which leads to severe visual impairment early in life.

Alongside the longer-term adult results, the three adolescents, followed for six months so far, also showed improvements in visual function. The company reported that both groups showed improved light sensitivity on full-field stimulus testing compared with their untreated eyes. The conference presentation also showed increased retinal sensitivity on microperimetry and a shift in fixation location toward the fovea. These measurements reflect light detection and localized retinal function, respectively, and cannot be directly equated with a comprehensive restoration of everyday vision.

The company also relayed participants’ reports of progress in recognizing family members, identifying objects, and walking independently, providing an everyday-life counterpart to the test results. However, these self-reports and objective measurements still need to be interpreted separately. Opus plans to continue with the low dose without further dose escalation and expects to begin Phase 3 dosing in the fourth quarter of 2026. According to the conference presentation, the primary efficacy endpoint requires an improvement of more than 7 decibels in mean retinal sensitivity across the central 16 test locations, establishing a clear threshold for subsequent validation.

Another therapy reported at the same meeting, OPGx-BEST1, targets retinal diseases associated with the BEST1 gene. The low-dose cohort in its Phase 1/2 BIRD-1 trial included five adults aged 31 to 63, with three to six months of follow-up. One participant could not complete microperimetry because their vision was too poor. Of the remaining four, three met the improvement criterion: a sensitivity increase of at least 3 decibels at at least five test points in the transition zone surrounding damaged tissue within the treated area. These are early results for localized light sensitivity and cannot yet be interpreted as three-quarters of patients having recovered their overall vision.

The BEST1 data also raise questions about how to measure efficacy. The research team combined multiple imaging methods to identify locations that still retain photoreceptor cells and may be more likely to respond to treatment, to help select testing areas in future studies. Averaging areas with different degrees of damage together could obscure localized changes. However, whether imaging can reliably predict treatment response still requires validation in subsequent studies.

Both sets of results currently come from interim data involving small numbers of participants, with shorter follow-up for the adolescents and the BEST1 cohort. BioPharm International also noted that the company’s announcement did not provide safety results for either therapy, so the overall risks and benefits cannot be assessed on that basis. The two-year follow-up adds evidence for the durability of the LCA5 therapy. Whether it can deliver reproducible improvements that are meaningful in everyday life for more patients remains to be determined by Phase 3 and more complete safety follow-up.

References

  1. Opus Genetics
  2. Opus Genetics — Rodrigo Jorge, University of São Paulo
  3. Opus Genetics
  4. BioPharm International